ZYBERNO
Stock Report
Updated Aug 26, 2026

GINKGO BIOWORKS HOLDINGS, INC. (DNABW)

Healthcare • OTC

$0.00

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
17.0/100
POOR BUSINESS
GINKGO BIOWORKS HOLDINGS, INC. (DNABW) scores 17/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-60.2%)
Debt-to-Equity (Solvency Risk):CRITICAL (2.01x)
Operating Margin (Operational Efficiency):CRITICAL (-259.9%)
Return on Capital (Capital Efficiency):CRITICAL (-28.6%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

GINKGO BIOWORKS HOLDINGS, INC. (DNABW) stock report — Zyberno Score 17/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, DNABW generated -$168.20M in Owner Earnings. Capital was deployed as follows: $1.98M invested in capital expenditures. Reinvestment rate: 23.5%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:0.00
Market Cap:$24.84K

Valuation Multiples (3)

P/B Ratio:0.00x
P/S Ratio:0.00x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$342.39M

Price Action & Momentum (1)

% of 52-Week High:2.1%
B. Profitability Assessment

Return Metrics (5)

ROA:-26.9%
Reinvestment Rate:23.5%
Fundamental Growth Rate (g):-6.7%

Margin Analysis (3)

Operating Margin Ttm:-259.9%
Net Margin Ttm:-260.0%
Ebitda Margin:-195.6%

TTM Performance (2)

Operating Margin Ttm:-259.9%
Net Margin Ttm:-260.0%

Yield Metrics (2)

Earnings Yield:-$1.41M
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:86.8%
Latest Earnings Filed:2026-02-26

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):-27.0%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:4.57x
Quick Ratio:4.57x
Cash Ratio:1.16x

Leverage Analysis (3)

Debt To Equity Ttm:2.01x
Debt-to-Equity Ratio:2.01x
Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:259,795,000.00
Cash And Cash Equivalents:84,535,000.00
Long Term Debt:$404.11M
Net Debt:$342.37M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $111.86M
Linear Growth: -27.0%
📊 Click to view full DNABW Revenue analysis & methodology →
Cost Of Revenue Ttm:$6.88M

Profitability Breakdown (2)

$440.58M-$290.69M

Bottom Line Performance (3)

-$290.80M
Income Before Tax:-$295.48M
Ebitda Ttm:-218,791,000.00

Operating Expenses (5)

Operating Expenses:402,554,000.00
R And D Expense:215,610,000.00
Sga Expense:159,573,000.00
Income Tax Expense:-$594.00K
Interest Expense:-5,336,000.00

Expense Ratios (3)

R And D To Revenue Percentage:1,069.7%
Sga To Revenue Percentage:791.7%
Ebitda Margin:-195.6%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$990.05M
Current Assets:$332.54M
Ppe Net:157,185,000.00
Goodwill:0.00
Intangible Assets:$44.39M

Liability Structure (4)

Total Liabilities:569,762,000.00
Current Liabilities:72,740,000.00
Long Term Debt:$404.11M
Short Term Debt:$22.79M

Equity & Capital (3)

Equity:$420.28M
Retained Earnings:-$6.28B
Common Stock:15,800,000,000.00

Working Capital Items (3)

Accounts Receivable:13,013,000.00
Inventory:0.00
Accounts Payable:9,575,000.00

Special Items (2)

Contract Liabilities:13,214,000.00
Stock Based Compensation:7,595,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$166.22M-$168.20M

Investment Activities (2)

Investing Cash Flow:$23.13M
Capital Expenditures Ttm:1,976,000.00

Financing Activities (3)

Financing Cash Flow:-$19.00K
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:19,469,000.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:71,900,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-5.00
-$5.64
Earnings Per Share Ttm:-$4.68

Revenue & Cash Per Share (2)

Sales Per Share Ttm:1.80
Operating Cash Flow Per Share:-$2.75

Book Value & Capital (2)

Book Value Per Share:$6.77
Cash Per Share:1.36

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.10x
Working Capital Turnover Ttm:0.43x

Receivables Management (2)

Receivables Turnover Ttm:8.60x
Days Sales Outstanding Ttm:42.46

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:508.27
Cash Conversion Cycle:-1,464.81
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:40.00
Quality Score:25.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$168.20M

Damodaran Growth Analysis (2)

Reinvestment Rate:23.5%
Fundamental Growth Rate (g):-6.7%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):-27.0%

Other Growth Rates (1)

Book Value Growth Rate (Linear):-32.3%
C. Company Profile & Context

Corporate Information (6)

Symbol:DNABW
Company Name:GINKGO BIOWORKS HOLDINGS, INC.
Sector:Healthcare
Industry:Biological Products, (No Diagnostic Substances)
Exchange:OTC
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:penny
Volume Category:N/A

Share Structure (3)

Shares Outstanding:62.09M
Shares Outstanding Basic:62.09M
Shares Outstanding Diluted:55.46M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-26 12:07:54 UTC
Data Timestamp:2026-08-26T12:07:54.682968
Scroll to Top